QiagenQGEN
About: Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
Employees: 5,800
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
48% more call options, than puts
Call options by funds: $52.2M | Put options by funds: $35.2M
7% more repeat investments, than reductions
Existing positions increased: 116 | Existing positions reduced: 108
4% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 50
4% less capital invested
Capital invested by funds: $6.9B [Q3] → $6.6B (-$308M) [Q4]
2% less funds holding
Funds holding: 325 [Q3] → 319 (-6) [Q4]
2.58% less ownership
Funds ownership: 69.01% [Q3] → 66.43% (-2.58%) [Q4]
50% less funds holding in top 10
Funds holding in top 10: 6 [Q3] → 3 (-3) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Baird Catherine Schulte 0% 1-year accuracy 0 / 20 met price target | 6%upside $42 | Neutral Downgraded | 19 Feb 2025 |
UBS John Sourbeer 0% 1-year accuracy 0 / 1 met price target | 21%upside $48 | Neutral Maintained | 7 Feb 2025 |
Morgan Stanley Steve Beuchaw 0 / 0 met price target | 25%upside $49 | Equal-Weight Downgraded | 6 Jan 2025 |
Financial journalist opinion
Based on 6 articles about QGEN published over the past 30 days









